Ken Bedi retweeted
Hume & colleagues demonstrate that #cardiomyocytes increase their ability to regrow following a #HeartAttack. Learn more at ahajrnls.org/49QNjQY
@n_palpant @realjosullivan @jameschong_doc @FairoojR @chenchenwenwen
Ken Bedi retweeted
Carley et al demonstrate that #CPT1 upregulation in response to pathological stress is an essential adaptive response. Learn how increasing CPT1 in #HF can mitigate pathological remodeling at ahajrnls.org/4pN1xbs
@VondriskaLab @kbedi88 @CPKyriakopoulos
Ken Bedi retweeted
Colleagues from many institutions have asked me how to get institutional investment / buy-in to start a central biobank.
Here is one helpful metric: To date, the @MassGenBrigham Biobank has led to $750M+ in grant funding for institutional investigators.
massgeneralbrigham.org/en/ab…
Ken Bedi retweeted
Research| Maddeb et al. show that while #HFpEF presents normal-looking contraction, the muscle looks abnormal, with disrupted contracting proteins, mitochondria and excess fat, particularly in the most obese patients.
👉rdcu.be/dPlJ7
Ken Bedi retweeted
We think this one is groundbreaking: Do you wonder how #SGLT2 inhibitors protect from heart failure? We show that #empagliflozen directly activates PANK1, rate-limiting for CoA synthesis, in human hearts. You read it here first! biorxiv.org/content/10.1101/…
Ken Bedi retweeted
Our Story is Out - on BioRxiv! Humbled to have worked with such a great team of scientists to investigating how #SGLT2 inhibitors provoke their astounding cardiac benefits.
We think this one is groundbreaking: Do you wonder how #SGLT2 inhibitors protect from heart failure? We show that #empagliflozen directly activates PANK1, rate-limiting for CoA synthesis, in human hearts. You read it here first! biorxiv.org/content/10.1101/…
Ken Bedi retweeted
Excited to share our new paper!
@Prosser_Lab @MarguliesLab @MCaporizzo
(shout out to @MCaporizzo incredible microscopy skills for the beautiful cardiomyocyte images)
tinyurl.com/bp98c8zt @ScienceTM
Ken Bedi retweeted
Absolutely thrilled to announce that the Tucker lab will be moving to SUNY Upstate Medical University in Syracuse, NY this September. Looking forward to awesome things ahead. @InnovateUpstate @UpstateNews @SUNY
Ken Bedi retweeted
In press @JACCJournals JACC:HF:
Low serum NT-proBNP in obese #HFpEF is related to lower myocardial synthesis despite same hemodynamic load.
Thanks to amazing team! @KSharmaMD @hildurkay Tess Peterson, Daniel Kikuchi, @SVungarala14 @dkassjhu
doi.org/10.1016/j.jchf.2024.…
Ken Bedi retweeted
New research examines the functional impact of alternative metabolic substrates in failing human cardiomyocytes ft. @AlexiaVite93, Timothy Matsuura, @kbedi88, Emily Flam, @AranyLab, @DanKellyPennCVI & @MarguliesLab (@PennCVI/ @PennCardiology) tinyurl.com/msp5hsma
Ken Bedi retweeted
Excited to share @AllofUsResearch program’s flagship genomics paper describing 245,388 clinical-grade genome sequences encompassing >1 billion genetic variants published today in @Nature
nature.com/articles/s41586-0…
Ken Bedi retweeted
Interested in TTN/DCM?
Check out current edition of @jclinicalinvest.
2 new reports: 1 by us w/ @Arany Lab and 1 from Miklos Kellermayer, plus commentary by @TravisHinson and Stuart Campbell.
We know a lot more about TTN pathomechanisms!
...and we know what we don't know. 🧵1/4
Ken Bedi retweeted
New paper alert! Led by @AlexiaVite93 : Functional Impact of Alternative Metabolic Substrates in Failing Human Cardiomyocytes
sciencedirect.com/science/ar…
@JACCJournals @AranyLab @DanKellyPennCVI @PennCVI @kbedi88
Ken Bedi retweeted
There was an incredible moment in clinic yesterday when I was able to tell a patient that her disease appeared to be *reversing*.
This is the first time in my life I have used those words.
Cardiac myosin inhibitors for hypertrophic cardiomyopathy are game changing. – at Stanford, CA
